# US 2021/0333235 A1 · Microchip capillary electrophoresis assays and reagents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0333235 A1
- Document ID: US20210333235A1
- Status: Published application
- Kind: A1
- Application number: 17/368,377
- Filed: 2021-07-06
- Published: 2021-10-28
- Earliest claimed: 2018-03-19
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Timothy Riehlman; Gabriel Carreau; Jeffrey Schneiderheinze; Nicole M. Nall
- Web page: https://patentgrep.com/patent/US20210333235A1

## CPC

- G01N 27/44747: {Composition of gel or of carrier mixture}
- G01N 27/44791: {Microapparatus (sample containers with integrated microfluidic structures B01L3/5027)}
- G01N 27/44726: {using specific dyes, markers or binding molecules}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Microchip Capillary Electrophoresis (MCE) assays and reagents to assess purity and to identify impurities in protein drug product samples are provided. Methods for analyzing analytes in a protein drug sample are provided.

## Claims

### Claim 1

An aqueous electrophoresis sample buffer, comprising:
155 to 200 mM 2-iodoacetamide;
0.50 to 1.5% lithium dodecyl sulfate; and
60 to 95 mM sodium phosphate,
wherein the aqueous electrophoresis sample buffer has a pH of less than or equal to 8.

### Claim 2 (depends on 1)

The aqueous buffer of claim 1, wherein the pH is 6.

### Claim 3 (depends on 1)

The aqueous buffer of claim 1, comprising 200 mM 2-iodoacetamide, 1.2% lithium dodecyl sulfate, and 60 mM sodium phosphate.

### Claim 4

An aqueous electrophoresis sample buffer, comprising:
165.9 mM 2-iodoacetamide,
0.81% lithium dodecyl sulfate, and
81 mM Sodium phosphate,
wherein the aqueous electrophoresis sample buffer has a pH of 6.0.

### Claim 5

An aqueous electrophoresis sample buffer, comprising:
200 mM 2-iodoacetamide,
1.2% lithium dodecyl sulfate, and
60 mM Sodium phosphate,
wherein the aqueous electrophoresis sample buffer has a pH of 6.0.

### Claim 6

An aqueous electrophoresis sample buffer, comprising:
200 mM 2-iodoacetamide,
1.2% lithium dodecyl sulfate, and
60 mM Sodium phosphate,
wherein the aqueous electrophoresis sample buffer has a pH of 8.0.

### Claim 7

An aqueous electrophoresis sample buffer, comprising:
0.50 to 1.5% lithium dodecyl sulfate;
45 to 75 mM sodium phosphate,
80 to 155 mM dithiothreitol,
wherein the aqueous electrophoresis sample buffer has a pH of 8 or greater.

### Claim 8 (depends on 7)

The aqueous buffer of claim 7, wherein the pH is 8.

### Claim 9 (depends on 7)

The aqueous buffer of claim 7, wherein the pH is 9.

### Claim 10 (depends on 8)

The aqueous buffer of claim 8, comprising 80 mM dithiothreitol.

### Claim 11 (depends on 8)

The aqueous buffer of claim 8, comprising 142 mM dithiothreitol.

### Claim 12 (depends on 7)

The aqueous buffer of claim 7, further comprising 1.2% lithium dodecyl sulfate and 60 mM sodium phosphate.

### Claim 13

An aqueous electrophoresis sample buffer, consisting of:
0.69% lithium dodecyl sulfate;
69 mM sodium phosphate, and
80 to 155 mM dithiothreitol,
wherein the aqueous electrophoresis sample buffer has a pH of 9.0.

### Claim 14

An aqueous electrophoresis sample buffer, consisting of:
1.2% lithium dodecyl sulfate;
60 mM sodium phosphate, and
80 mM dithiothreitol,
wherein the aqueous electrophoresis sample buffer has a pH of 8.0.

### Claim 15 (depends on 1)

A method for identifying contaminants or impurities in a protein drug sample, the method comprising the steps of:
adding the protein drug sample to the buffer of claim 1 to form a buffered protein drug sample;
heating the buffered protein drug sample to 45 to 75° C. for 5 to 15 minutes to form a denatured buffered protein drug sample;
adding a detectable label to the denatured buffered protein drug sample and heating it at 30 to 40° C. for 10 to 40 minutes to form a denatured labeled protein drug sample;
diluting the denatured labeled protein drug sample and subjecting it to MCE to separate the diluted protein drug sample on a microchip capillary electrophoresis system to produce an electropherogram; and
identifying peaks in the electropherogram corresponding to the protein drug, contaminants, and/or impurities.

### Claim 16 (depends on 15)

The method of claim 15, wherein the buffered protein drug sample is heated at 60° C. for 10 min.

### Claim 17 (depends on 15)

The method of claim 15, wherein the labeled protein drug sample is heated at 35° C. for 15 minutes.

### Claim 18 (depends on 15)

The method of claim 15, wherein the diluted protein drug sample is 3.6 μg/ml.

### Claim 19 (depends on 5)

A method for identifying contaminants or impurities in a protein drug sample, the method comprising the steps of:
adding a protein sample to the buffer of claim 5 to form a buffered protein drug sample;
heating the buffered protein drug sample to 45 to 75° C. for 5 to 15 minutes to form a denatured protein drug sample;
adding a detectable label to the denatured protein drug sample and heating it at 30 to 40° C. for 10 to 40 minutes to form a denatured labeled protein drug sample;
diluting the denatured labeled protein drug sample and subjecting it to MCE analysis on a microchip capillary electrophoresis system to produce an electropherogram; and
identifying peaks in the electropherogram corresponding to contaminants or impurities.

### Claim 20 (depends on 19)

The method of claim 19, wherein the buffered protein drug sample is heated at 60° C. for 10 min.

### Claim 21 (depends on 19)

The method of claim 19, wherein the sample is heated at 35° C. for 15 minutes.

### Claim 22 (depends on 19)

The method of claim 19, wherein the diluted protein drug sample is 3.6 μg/ml.

### Claim 23 (depends on 19)

The method of claim 19, wherein the detectable label is DY-631 N-hydroxysuccinimidyl ester.

### Claim 24 (depends on 22)

The method of claim 22, wherein the detectable label is reconstituted with dimethyl sulfoxide (DMSO) followed by dilution with 200 mM Sodium Phosphate pH 7.2 buffer.

### Claim 25 (depends on 1)

A kit comprising the buffer according to claim 1, and written instructions for preparing a sample for electrophoresis in the buffer.
